Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

Diabetes Care

Volumn 35, Issue 11, 2012, Pages 2174-2181

  Hirsch, Irl B ^a   Bode, Bruce ^b   Courreges, Jean Pierre ^c   Dykiel, Patrik ^d   Franek, Edward ^e   Hermansen, Kjeld ^f   King, Allen ^g   Mersebach, Henriette ^d   Davies, Melanie ^h  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Atlanta Diabetes Association   (United States)

^c General Hospital   (France)

^d NOVO NORDISK A S   (Denmark)

^e MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g Diabetes Care Center   (United States)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLEXPEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DETEMIR; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; OPEN STUDY; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; VITAL SIGN; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, LONG-ACTING; MEALS;

EID: 84868133240     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2503     Document Type: Article

References (45)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. Morris AD, Boyle DI, McMahon AD, Greene SA, MacDonald TM, Newton RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350:1505- 1510
3. Kitzler TM, Bachar M, Skrabal F, Kotanko P. Evaluation of treatment adherence in type 1 diabetes: a novel approach. Eur J Clin Invest 2007;37:207-213
4. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-245
5. Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns 2007;68:10-15 (Pubitemid 47126791)
6. Di Battista AM, Hart TA, Greco L, Gloizer J. Type 1 diabetes among adolescents: reduced diabetes self-care caused by social fear and fear of hypoglycemia. Diabetes Educ 2009;35:465-475
7. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176
8. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2010;39:641-654
9. The DCCT Research Group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991;90:450-459
10. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Beck RW, Hirsch IB, Laffel L, et al. The effect of continuous glucosemonitoring in well-controlled type 1 diabetes. Diabetes Care 2009;32:1378-1383
11. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9:209-217 (Pubitemid 46502039)
12. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab 2007;9:799-812 (Pubitemid 47555203)
13. Zachariah S, Sheldon B, Shojaee-Moradie F, et al. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Diabetes Care 2011;34:1487-1491
14. Hendriksen KV, Jensen T, Oturai P, Feldt-Rasmussen B. Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients. Diabetologia 2012;55:46-50
15. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec (Abstract).Diabetologia 2011;54(Suppl. 1):S426
16. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29:2104-2114
17. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetologia 2011;54(Suppl. 1):S425
18. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14:859-864
19. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a newgeneration ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011;34:661-665
20. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1489-1497
21. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation (Abstract). J Pept Sci 2010;16:32
22. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 1993;10:535-539 (Pubitemid 23189758)
23. Vaag V, Leiter LA, Franek E, et al. IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30. Abstract presented at the 47th Annual Meeting of the European Association for the Study of Diabetes, 12-16 September 2011, Lisbon, Portugal
24. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's Manual for the SF-36v2(R) Health Survey. 2nd ed. Lincoln, RI, QualityMetric Incorporated, 2007
25. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724-736 (Pubitemid 38736962)
26. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005;7:73-82
27. Kølendorf K, Ross GP, Pavlic-Renar I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med 2006;23:729-735 (Pubitemid 44366070)
28. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007;24:27-34 (Pubitemid 46103068)
29. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25:442-449 (Pubitemid 351490120)
30. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274 (Pubitemid 44125921)
31. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581 (Pubitemid 44856694)
32. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-923
33. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-1620 (Pubitemid 38697678)
34. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290-299 (Pubitemid 46502046)
35. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab 2005;31(4 Pt. 2):4S25-4S33
36. Meneghini L, Atkin S, Bain S, et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes (Abstract). Diabetes 2011;60(Suppl. 1A):LB10
37. Bolli GB, Kerr D, Thomas R, et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32:1170-1176
38. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009;31:2086-2097
39. Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441-454 (Pubitemid 47526934)
40. Le Floch JP, Lévy M, Mosnier-Pudar H, et al.; Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT) Study Group. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009;32:32-37
41. Poon K, King AB. Glargine and detemir: Safety and ef ficacy profiles of the longacting basal insulin analogs. Drug Healthc Patient Saf 2010;2:213-223
42. Szypowska A, Golicki D, Groele L, Pańkowska E. Long-acting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn 2011;121:237-246
43. Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins for the treatment of type 2 diabetes. Expert Opin Pharmacother 2010;11:2027-2035
44. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, a new generation ultralong acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine (Abstract).Diabetes 2010;59(Suppl. 1):A11
45. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011;34:669-674